Nintedanib and Pembrolizumab – Hope for Mesothelioma Patients
The latest findings in cancer treatments for the often fatal mesothelioma have scientists and researchers hopeful that they are one step closer in finding a consistent, effective treatment for the asbestos-caused cancer. The LUME-Meso Phase II trial for patients with malignant pleural mesothelioma focused on the administration of the triple angiokinase inhibitor called Nintedanib. This oral treatment is designed to block cancer growth by hindering protein kinases in cancer cells and stop cancer cell from growing their own blood vessels. The latest completed clinical trial (Phase II) showed progression-free survival goal was met. Progression-free survival is the amount of time after treatment that...
Continue reading